Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

App aims to turn bystanders into lifesavers against opioid overdoses

NCT ID NCT06238128

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 20, 2026 · Updated 4 times

Summary

This study tested a new system called the Opioid Rapid Response System (ORRS) that uses a smartphone app to train and alert everyday people to respond to opioid overdoses with the life-saving drug naloxone. Over 700 adults from communities using the PulsePoint app took part. The goal was to see if this approach could increase knowledge, confidence, and willingness to help during an overdose emergency.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

773 people

The number who actually took part.

Started

May 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Citizens who live in participating PulsePoint communities * Must to be 18 and older * Must be fluent in English * Must have access to the mobile data and able to download and use apps in a smartphone Exclusion Criteria: * Citizens who do not live in participating PulsePoint communities * Under 18-year-old * Citizens who are not fluent in English * Citizens who do not have access to mobile data and unable to download and use apps in a smartphone.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opioid overdose are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ewald & Wasserman Research Consultants, LLC

    San Francisco, California, 94104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.